Compare AbbVie Inc (ABBV) vs Coupang Inc (CPNG) Price & Performance

AbbVie (ABBV) trades at $249.94, up 0.82% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with $61.16B revenue in 2025 and consistent earnings beats, though net margins have compressed from 20.4% in 2022 to 6.9%. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional accumulation signal confidence. Technical indicators show support at $248 and resistance at $251, with the stock trading near analyst consensus targets.

Outlook remains positive with 70.7% analyst buy ratings and $278.69 price target, representing 11.5% upside. Key opportunities include immunology growth from Skyrizi/Rinvoq and pipeline advancements. Risks include patent cliffs in the 2030s, debt levels at 50.4% of assets, and margin pressure from competitive and pricing headwinds. The dividend yield and earnings recovery in 2026 forecast support the bullish case.

Coupang (CPNG) trades at $16.42, up 1.42% on the day, with technical indicators showing a neutral to bearish bias as the stock consolidates near key support levels. The company reported mixed Q2 2026 results with revenue acceleration but missed earnings expectations, while maintaining strong revenue growth trends and positive operating cash flow of $1.77 billion in 2025. Recent news highlights Coupang's debut on the Fortune Global 500 and ongoing recovery from a data breach incident.

Despite near-term earnings pressure and regulatory challenges, Coupang maintains dominant market position in South Korean e-commerce with expanding Taiwan operations. Wall Street remains overwhelmingly bullish with 87.5% buy ratings and a $23.38 consensus price target representing 42% upside potential, though investors should monitor execution on profitability targets and resolution of the $422 million regulatory fine.